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OBJECTIVE: Mammography has been established as the gold standard for the detection of breast cancer, and
imaging techniques such as ultrasonography, magnetic resonance imaging, scintigraphy and positron emission
tomography may be useful to improve its sensitivity and specificity. The objective of this study with breast
scintigraphy was to evaluate the uptake of 99mTc-thymine in mammary lesions.
METHODS: A total of 45 patients were included in this study. Thirty-three patients (73%) were subjected to
surgery or percutaneous biopsy, providing histopathological data. The other 12 patients who remained under
surveillance received clinical examinations and biannual mammography with a normal follow-up of at least
three years, the data from which were used for comparison with the scintimammography results.
RESULTS: The majority of patients (64.4%) had clinically impalpable lesions with a mammogram diagnosis of
microcalcifications, impalpable nodules, or focal asymmetry. Of the studied lesions, 87% were smaller or equal
to 20 mm in diameter, and 22% had malignant histopathological findings. Scintigraphy with 99mTc-thymine
had a sensitivity of 70%, a specificity of 85.7%, positive and negative predictive values of 58.3% and 90.9%,
respectively, and an accuracy of 82.2%.
CONCLUSIONS: The results of this study are consistent with those previously reported by other authors. The
good specificity and high negative predictive value of this technique and the absence of uptake in the heart
indicate that it may be a promising complementary method in clinical practice and that it may contribute to
reducing unnecessary benign biopsies.
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& INTRODUCTION
Breast cancer is a major public health problem, the
incidence and mortality of which are continuously increas-
ing. Breast cancer represents the most common malignancy
in women, affecting more than one million individuals
every year worldwide (1,2).
An early diagnosis of breast cancer may result in a better
prognosis. Thus, regular screenings are recommended by
health systems around the world. Mammography has been
established as the gold standard method for the detection of
breast cancer (3-5). The efficacy of cancer screening using
mammography has been demonstrated in both randomized
trials and observational studies (3-5). Mammographic
screening reduces the mortality from breast cancer in
women between 40 and 69 years of age by 20 to 35% (4,6).
However, not all malignancies are detected using this
screening method. Major factors that lead to false-negative
findings using mammography include breast density,
implants, severe dysplastic disease, and significant archi-
tectural distortion following breast surgery or radiation
therapy (7-10).
Approximately 90 to 95% of women with abnormal
mammogram findings do not have breast cancer. The
relative inefficiency reflected by this statistic highlights the
necessity of new diagnostic methods that can improve the
sensitivity and specificity of mammography (10,11). The
development of improved non-invasive diagnostic methods
for the screening of breast lesions is needed, which would
reduce the requirement for invasive procedures such as
breast biopsy for a precise diagnosis (10,11). Conventional
biopsies, in addition to the potential for the involvement of
hospitalization, anesthesia, and clinical complications, are
unnecessary in 80% of cases and may induce changes in the
Copyright  2013 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.




breast parenchyma that hinder subsequent mammographic
readings (4,10). In addition, procedures such as percuta-
neous or surgical biopsy can cause anxiety, inconvenience,
and discomfort to the patient and can add medical costs to
both the patient and the health care system (10-12).
In the last decade, progress in pharmacology combined
with evolving technology has enabled the establishment of
scintimammography as a non-invasive technique for the
localization and staging of malignant tumors of the breast
using molecules such as Sestamibi and Tetrofosmin labeled
with technetium-99m (99mTc) (13-15). Other molecules such
as 99mTc(V) dimercaptosuccinic acid (DMSA) and 99mTc-
labeled alkyl triphenyl phosphonium (99mTc-Mito10-
MAG3) are also being studied to improve detection
(16,17). The quality of scintimammography is not compro-
mised by breast density, which limits the effectiveness of
mammography particularly in young women. Breast scinti-
graphy has a major indication for select groups of patients
with dense breasts; patients using hormone therapy;
patients suspected of having recurrent disease resulting in
architectural distortions secondary to previous surgery;
patients undergoing chemotherapy or radiotherapy or
who have breast implants; and patients at high risk for
breast cancer (15,18-21). Scintimammography is also useful
for the study of breast cancer multicentricity (13,15).
A recent meta-analysis of 42 studies that used ultrasound,
computed tomography (CT), magnetic resonance imaging
(MRI), scintimammography, and positron emission tomogra-
phy (PET) determined that MRI seemed to be a more useful
complement to existing surveillance methods to assess patients
with suspected recurrent and/or metastatic breast cancer (17).
Although MRI can be applied in these patient populations, its
usage is limited by higher costs and a higher rate of false-
positive results compared with mammography (4).
In previous reports, we presented the use of 99mTc-
thymine in the evaluation of nodules and the thickening of
breast tissue. The pattern of 99mTc-thymine uptake could
differentiate malignant lesions of the breast from benign
lesions and breast densities in which there is uptake of the
radiopharmaceutical (22). We also compared the uptake of
99mTc-thymine and 99mTc-sestamibi in malignant breast
lesions and found that 99mTc-thymine exhibited higher
sensitivity, specificity, accuracy, and positive predictive
values compared to 99mTc-sestamibi (19).
Here, we evaluated the use of 99mTc-thymine for the
study of malignant microcalcifications and initial palpable
and impalpable malignant lesions of the breast.
& METHODS AND MATERIALS
Study subjects consisted of 45 patients of the gynecology
and mastology services of two public hospitals. Inclusion
criteria were: (I) patients who detected changes in their
breast self-examination, (II) patients with microcalcifications
detected using mammography consisting of asymmetry or
focal nodules smaller or equal to 25 mm in diameter, and
(III) patients with BI-RADSH categories 3, 4, or 5. We
excluded patients based on the following criteria: (I) breast
lesions greater than 25 mm in diameter, (II) prior chemo or
hormone therapy, (III) breast surgery or prior homolateral
radiotherapy, and (IV) pregnancy or lactation.
The BI-RADS system includes categories that are used to
standardize interpretation of mammograms among radiolo-
gists (23). BI-RADS assessment categories can be summarized
as: Category 0 - need additional imaging evaluation;
Category 1 - negative; Category 2 - benign finding;
Category 3 - probably benign finding - follow-up in a short
time frame is suggested; Category 4 - suspicious abnorm-
ality, biopsy considered; Category 5 - highly suggestive of
malignancy, appropriate action needed; Category 6 - known
biopsy - proven malignancy.
The average age of the patients studied was 49.9 years
and ranged from 26 to 80 years. All patients were informed
about the procedure and, after acceptance for inclusion in
the study, signed a written informed consent. The research
protocol was approved by the research ethics committee of
the institution.
To evaluate breast lesions, 370 MBq (10 mCi) of 99mTc-
thymine was injected intravenously into the forearm,
contralateral to the breast with the lesion. Patients were
placed in a prone position on a foam mattress, and the
studied breast was positioned tomake it accessible. The other
breast remained compressed to themattress. The homolateral
arm of the affected breast was placed above the patient’s
head in a position as comfortable as possible. The surface of
the collimator (a device of the gamma camera that is capable
of collimating radiation to produce the patient’s images)
touched the side of the body with the studied breast.
Counts were acquired in a 15% window centered at
140 keV. The acquisition of images was initiated 15 minutes
after the administration of 99mTc-thymine, and each
acquisition lasted for 10 minutes. Both breasts were
evaluated. The first lateral image obtained was of the breast
without lesions, followed by the breast with the suspected
tumor. Following image acquisition, the patient was placed
in the supine position with the hands behind the head.
Planar images were analyzed separately by two nuclear
medicine physicians and, when the opinions were discor-
dant, the results were determined by consensus. Using a
qualitative analysis of images, scintigraphy was considered
positive when there was a high uptake of the radio-
pharmaceutical in a segment of the breast. Scintigraphy
was considered negative in cases where there was a
homogeneous distribution of the radiopharmaceutical in
both breasts.
The data were evaluated by the analysis of the sensitivity,
specificity, positive and negative predictive values, and
measures of accuracy (confidence interval of 95%; 95% CI)
for scintigraphy in relation to the standard for histology
(positive and negative).
The histopathological samples were obtained from study
patients with breast mammography results with BI-RADSH
classifications of category 4 or 5, which included 33 patients.
Twelve patients with BI-RADSH classification of category 3
had been recommended for monitoring with biannual
mammography. We used the follow-up period of three
years and the radiological gold standard for comparison
with the outcome of breast scintigraphy in these patients.
The degree of agreement was evaluated using the Kappa
coefficient. The criterion for determination of significance
was 5%.
& RESULTS
Thirty-three of the 45 patients studied (73%) were
subjected to surgery or percutaneous biopsy, providing
histopathological data. The patients (n = 12) that remained
under surveillance received clinical examinations and
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biannual mammography with a normal follow-up of at least
three years, the data from which were used for comparison
with the scintimammography results.
A majority of patients (29/45; 64.4%) had clinically
impalpable lesions with a mammogram diagnosis of
microcalcifications, impalpable nodules, or focal asymme-
try. Sixteen patients (35.6%) had palpable lesions. Clustered
microcalcifications, which were or were not associated with
a nodule, were present in 24/45 patients (53%). Among the
studied lesions, 87% were smaller or equal to 20 mm in
diameter (41/47). Two patients had two lesions.
Ten (22%) of the 45 patients studied had malignant
histopathological findings (11 lesions - eight cases of
infiltrating ductal carcinoma, one case of in situ ductal
carcinoma and invasive lobular carcinoma, and one case of
cribriform type intraductal carcinoma. All patients with
confirmed breast cancer were between 42 and 75 years old.
In comparison with breast mammography, 7/10 of the
cancer cases were correctly identified by breast scintigraphy
with 99mTc-thymine. In three patients (3/10), breast
scintigraphy showed false-negative results (a palpable
nodule with normal mammogram, an irregular nodule
suspected for malignancy, and clustered microcalcifications
on mammography).
Thirty patients with negative breast scintigraphy results
had histopathology and/or radiological follow-up for three
years. Four patients who had positive breast scintigraphy
had benign histopathological biopsies. The false-positive
results were: two cystic nodules, one fibroadenoma, and an
atypical hyperplasia. In one patient (BI-RADSH 3) with a
positive breast scintigraphy, histopathological examination
was not performed by decision of the mastology service,
which followed the patient for three years. Table 1 shows
the patients’ characteristics, Table 2 lists the measures of
accuracy of the patients studied, and Table 3 shows the
patients sorted by BI-RADS.
We observed a significant concordance (Kappa= 0.520,
standard error = 0.147, p= 0.0002) between the diagnosis by
scintigraphy and the pattern of histology, but it was of a
moderate degree. Figure 1 illustrates a normal distribution
of 99mTc-thymine scintigraphy in the anterior view with a
high liver uptake. We can observe that there is no heart
uptake. Figure 2 is an example of a negative scintigraphy
image obtained with 99mTc-thymine. A homogenous
distribution of the radiopharmaceutical can be observed in
both breasts. Figure 3 shows an example of a positive
scintigraphy image obtained with 99mTc-thymine in which
an increased uptake of the radiopharmaceutical is observed
in the region of the right breast nodule.
& DISCUSSION
Although the efficacy of mammography has been
demonstrated, perfect sensitivity or specificity is not
achieved in women undergoing screening. As such, the
issue of adverse consequences for women who do or do not
have breast cancer has been a source of growing attention
(15,24,25).
If breast cancer screening is to be successful, the majority
of cancers among screened women must be detected when
tumors are small and before the occurrence of distant or
nodal metastases. To achieve this, a combination of imaging
modalities may be superior to any single screening
technique (9). 99mTc-sestamibi and 99mTc-tetrofosmin
were first described as myocardial perfusion tracers due to
their property of accumulating in cells with higher
mitochondrial activity and demonstrating perfused myo-
cardium in contrast with ischemic and fibrotic regions.
Afterwards, they were applied to detect tumors based on
the principle that tumors such as breast cancer generally
have higher mitochondrial activity than the surrounding
cells. Despite promising initial results, breast scintigraphy
with 99mTc-sestamibi is not yet included in the routine
diagnosis of breast cancer. The sensitivity of the method was
reported to range from 84 to 96% in initial studies, and the
specificity ranged from 86 to 100% (13,26,27). However, in
more recent publications, particularly in multicenter studies
in which a large number of palpable and impalpable lesions
were studied, sensitivity and specificity were both reduced
(28-30).
Tiling et al. (31) reported that tumor size appears to be
crucial in limiting the capacity of scintigraphy to detect
breast cancer, and a number of studies have also identified a
correlation between the sensitivity of breast scintigraphy
and the diameter of the tumor (29,31).
In a modified meta-analysis of the use of 99mTc-sestamibi
for the diagnosis of initial breast cancer in 2,727 lesions,
Khalkhali and Itti (32) stated that the overall sensitivity and
specificity of breast scintigraphy were 83.3% and 81.3%,
respectively. The overall sensitivity reported included
palpable and impalpable lesions, which likely explains the
difference in reported results in this and other reviews (32).
In a multicenter study to assess the effectiveness of breast
scintigraphy with 99mTc-sestamibi in 1243 women with
33% palpable lesions, Sampalis et al. (33) concluded that
breast scintigraphy was highly effective and potentially
useful as a complement to mammography for the early
detection of breast cancer. These authors reported a
sensitivity and specificity of 93% and 87%, respectively,
with a negative predictive value of 98% and a positive
predictive value of 58% (33).
We previously described a technique for the labeling of
thymine, a thymidine precursor, with 99mTc. (19,22). Here,
we obtained a sensitivity of 70%, a specificity of 85.7%, an
accuracy of 82.2%, and positive and negative predictive
values of 58.3% and 90.9%, respectively. It is noteworthy
that the total number of patients was 45, which were
divided into two groups following BI-RADSH 3 classifica-
tion: one (n= 33) with histopathological results and the other
(n = 12) without biopsy. The false-positive results in most of
the other studies using 99mTc-sestamibi resulted from the
presence of fibroadenoma, atypical hyperplasia, fibrocystic
disease, and inflammatory disease (26,31,34,35). In our
study, the four false-positive results also consisted of
fibrocystic breast changes (two cases), fibroadenoma (one
case), and one case of atypical hyperplasia. Patients with
atypical hyperplasia have been shown to have an increased
relative risk for breast cancer and a higher incidence of
positive breast scintigraphy (36). The results of 99mTc-
sestamibi scintigraphy are least useful in cases of breast
microcalcifications and in situ carcinoma, as reported by
Gommans et al. (37). Moreover, unlike 99mTc-thymine, the
myocardial uptake of the 99mTc-sestamibi is relatively high,
which leads to greater background activity due to the
proximity to breast tissues. Despite this, intravenously
administered 99mTc-thymine has the potential advantage
of being used in radioguided surgeries to detect impalpable
breast lesions without conventional Radioguided Occult
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Lesion Localization (ROLL) and Sentinel Node and Occult
Lesion Localization (SNOLL) techniques.
In nearly all reports of breast scintigraphy, 99mTc-
sestamibi or 99mTc-tetrofosmin was used. The 99mTc-
thymine results in this study are consistent with those
reported by other authors (30,38), even though the majority
of patients in this study had impalpable lesions.
To be an acceptable complementary method to mammo-
graphy, breast scintigraphy must provide high specificity.
We obtained a high level of specificity and a high negative
Table 1 - Patient characteristics.





(mm) Scintigraphy Biopsy Histopathology
1 80 UOQ R Yes 4 NEG NEG Fibrocystic disease
2 58 Retroareolar R 4 POS POS IDC (15 mm)
3 52 UOQ L Yes 4 NEG NEG Fibrocystic disease




5 52 UOQ L 3 25 NEG Follow-up -
6 50 UOQ L Yes 4 POS NEG Fibrocystic disease
7 55 UIQ L Yes 4 NEG NEG Usual ductal
hyperplasia
8 46 LIQ L Yes 3 18 and 7 NEG Follow-up -
9 43 UOQ L 4 18 POS POS IDC (18613 mm)
10 67 Retroareolar L Yes 3 NEG Follow-up -
11 50 Asymmetry on
UOQ, UIQ
R 3 NEG Follow-up -
12 54 UIQ and UOQ R 4 17 NEG NEG Fibrocystic disease
13 61 UOQ R 3 12 NEG Follow-up -
14 68 UOQ L 4 15 NEG NEG Fibrocystic disease
15 56 UIQ L 4 25 NEG NEG -
16 30 Retroareolar L 3 25 NEG Follow-up -
17 61 UOQ L Yes 4 NEG NEG Fibrocystic disease
18 56 UOQ L Yes 3 NEG Follow-up -
19 55 Asymmetry on LIQ
and UIQ
L 3 NEG Follow-up -
20 65 UOQ R Yes 4 NEG Follow-up -
21* 36 LIQ R+L Yes (L) 4 20 (R) POS (R) NEG Fibroadenoma
22 67 LOQ L Yes 4 NEG NEG Fibrocystic disease
23 58 UOQ R 4 13 NEG NEG Fibrocystic disease
24 39 UIQ R 4 15 POS NEG AEH
25 75 UOQ L 5 POS POS IDC (10 mm)
26 70 LIQ L Yes 4 NEG NEG -
27 45 LIQ R Yes 4 NEG NEG -
28 68 UOQ L 5 25 NEG POS IDC (25 mm)
29 54 UOQ L Yes 4 NEG Follow-up -
30 61 UOQ L Yes 4 NEG NEG -
31 55 UOQ R Yes 4 NEG POS IDC (10 mm)
32 61 Subareolar L Yes 4 POS POS Cribriform IDC
(20 mm)
33 26 UOQ R 4 20 NEG NEG Fibroadenoma
34 67 Retroareolar R Yes 4 NEG NEG Fibrocystic disease,
adenosis
35 63 Asymmetry, LIQ L 4 NEG NEG -
36 62 UOQ and LOQ L Yes 4 NEG NEG Fibrocystic disease,
adenosis, usual ductal
hyperplasia
37 50 UOQ L Yes 4 POS NEG Fibrocystic disease,
adenosis
38 58 UOQ L Yes 4 NEG NEG Adenosis, usual ductal
hyperplasia
39 58 Asymmetry R 4 POS POS IDC (20 mm)
40 44 Asymmetry L 4 NEG POS IDC (25 mm)
41 48 UOQ L 4 POS POS IDC (23 mm)
42 49 UOQ R 4 20 NEG NEG Fibrocystic disease
43 48 UIQ and LIQ R Yes 4 NEG NEG
44 36 UIQ and LIQ L Yes 4 NEG Follow-up -
45 50 LIQ L 4 8 POS Follow-up -
Abbreviations: UOQ, upper outer quadrant; UIQ, upper inner quadrant; LOQ, lower outer quadrant; LIQ, lower inner quadrant; AEH, atypical epithelial
hyperplasia; IDC, invasive ductal carcinoma; NEG, negative; POS, positive; R, right; L, left.
*Lesions in both breasts.
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predictive value in this breast scintigraphy study. These
make this test attractive because of the potential to reduce
unnecessary biopsies. Other studies have reported a better
sensitivity but a lower specificity than those reported in this
study (39). Although the early detection of breast cancer
needs to be improved with the development of equipment
that can discover smaller lesions, the employment of 99mTc-
thymine seems to be more advantageous than other radio-
pharmaceuticals because it is a precursor to a DNA
nitrogenous base that plays an important role in tumoral
growth. Some of the main characteristics of the metabolism of
tumor cells are the increase of glycolysis and mitochondrial
activity, the synthesis of nucleic acids, and the production of
proteins previous to mitosis. Unlike methods that simply
demonstrate an increase in mitochondrial activity, which
may occur in tissues that are not under cell division, 99mTc-
thymine has the potential to demonstrate the synthesis of
nucleic acids related to tumor growth. This effect increases
the sensitivity and specificity of tumor detection.
Recently, Sun et al. (40) imaged DNA synthesis with PET
using 18F- 1-(2’-deoxy-2’-fluoro-beta-D-arabinofuranosyl)
thymine (FMAU), a pyrimidine analogue that is phosphory-
lated by thymidine kinase and incorporated into DNA.
Their results demonstrated that 18F-FMAU was selectively
retained in the DNA of proliferating cells and was resistant
to degradation (40). We have similarly shown that 99mTc-
thymine is incorporated into cellular DNA (22). Unlike PET
and PET-CT, which require expensive equipment with
limited availability worldwide, conventional gamma cam-
eras are able to perform SPECT imaging and are much more
readily available. Therefore, the use of 99mTc-thymine as a
radiopharmaceutical for SPECT imaging has the potential
for broader use.
It is important to note that our study has limitations; for
instance, our study included a great number (87%) of lesions
smaller or equal to 20 mm and few patients with malignant
lesions. These factors could explain the lower sensitivity that
we report for scintigraphy. Further studies are needed to
provide a greater understanding of the application of this
technique in these two groups. Nonetheless, the high level of
specificity and the high negative predictive value of this
technique indicate that the use of breast scintigraphy with
99mTc-thyminemay be a promising complementarymethod,
particularly in selected patients. It may be a useful adjunct
method in high-risk patients such as those with prior breast
cancer, a very strong family history of breast cancer, lobular
cancer in situ, or Paget disease. Scintimammography may
also be helpful for the study of borderline lesions of BI-RADS
categories 3 and 4 or patients under evaluation for recurrence
and adjuvant chemotherapy. Therefore, scintimammography
Table 2 - Measures of accuracy of scintigraphy using
99mTc-thymine for the diagnosis of breast cancer.
Measures % LL 95% UL 95%
Sensitivity 70.0 41.6 98.4
Specificity 85.7 74.1 97.3
Positive Predictive Value 58.3 30.4 86.2
Negative Predictive Value 90.9 81.1 100
Accuracy 82.2 71.1 93.4
LL 95%: Lower limit of 95%; UL: Upper limit of 95%.











BI-RADS 3 8 52.1¡11.1 38% 18.5¡8.0
BI-RADS 4 34 54.3¡11.1 44% 17.1¡4.7
BI-RADS 5 3 61.7¡17.4 33% 17.1¡11.2
Figure 1 - Scintigraphy shows a normal distribution of 99mTc-
thymine in anterior view with high liver uptake and no heart
uptake.
Figure 2 - A 52-year-old woman with a focal asymmetric density
in the lower internal quadrant of the right breast on mammo-
graphy (BI-RADSH 3). This image shows a negative 99mTc-
thymine scintigraphy (no uptake).
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may be a valuable tool in clinical practice that can reduce the
number of unnecessary benign biopsies.
& ACKNOWLEDGMENTS
This study was supported by grants from Fundac¸a˜o Carlos Chagas Filho de
Amparo a` Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho
Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq).
& AUTHOR CONTRIBUTIONS
Ribeiro MP contributed to the screening of the patients, design and writing
of the paper. Souza SA, Fonseca LM, and Gutfilen B contributed to the
execution of scintigraphy, discussion of the results, design and writing of
the paper. Lopes FP contributed to the discussion of the results, design and
writing of the paper. Castro PH contributed to the design and writing of
the paper.
& REFERENCES
1. Ferlay A, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.
GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 10 [Internet]. Lyon, France: International Agency for
Research on Cancer; 2010.
2. Instituto_Nacional_de_Caˆncer. Estimativa da incideˆncia de caˆncer no
Brasil. Brasil: Ministe´rio da Sau´de; 2012; Available from: http://www1.
inca.gov.br/estimativa/2012.
3. Gotzsche PC, Nielsen M. Screening for breast cancer with mammogra-
phy. Cochrane Database Syst Rev. 2009(4):CD001877.
4. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP,
3rd, et al. American Cancer Society guidelines for breast cancer
screening: update 2003. CA Cancer J Clin. 2003;53(3):141-69, http://dx.
doi.org/10.3322/canjclin.53.3.141.
5. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United
States, 2012: A review of current American Cancer Society guidelines
and current issues in cancer screening. CA Cancer J Clin. 2012 Jan 19.
doi: 10.3322/caac.20143. [Epub ahead of print]
6. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W,
Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh
randomised trial of breast-cancer screening. Lancet. 1999;353(9168):1903-
8, http://dx.doi.org/10.1016/S0140-6736(98)07413-3.
7. Nothacker M, Duda V, Hahn M, WarmM, Degenhardt F, Madjar H, et al.
Early detection of breast cancer: benefits and risks of supplemental
breast ultrasound in asymptomatic women with mammographically
dense breast tissue. A systematic review. BMC Cancer. 2009;9:335,
http://dx.doi.org/10.1186/1471-2407-9-335.
8. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM,
Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer
screening in women with a familial or genetic predisposition.
N Engl J Med. 2004;351(5):427-37.
9. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe
MJ, et al. Comparison of breast magnetic resonance imaging, mammo-
graphy, and ultrasound for surveillance of women at high risk for
hereditary breast cancer. J Clin Oncol. 2001;19(15):3524-31.
10. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-
year risk of false positive screening mammograms and clinical breast
examinations. N Engl J Med. 1998;338(16):1089-96.
11. Kerlikowske K, Smith-Bindman R, Ljung BM, Grady D. Evaluation of
abnormal mammography results and palpable breast abnormalities. Ann
Intern Med. 2003;139(4):274-84.
12. Liang W, Lawrence WF, Burnett CB, Hwang YT, Freedman M, Trock BJ,
et al. Acceptability of diagnostic tests for breast cancer. Breast Cancer Res
Treat. 2003;79(2):199-206, http://dx.doi.org/10.1023/A:1023914612152.
13. Lumachi F, Zucchetta P, Marzola MC, Ferretti G, Povolato M, Paris MK,
et al. Positive predictive value of 99mTc sestamibi scintimammography
in patients with non-palpable, mammographically detected, suspicious,
breast lesions. Nucl Med Commun. 2002;23(11):1073-8, http://dx.doi.
org/10.1097/00006231-200211000-00006.
14. Taillefer R. The role of 99mTc-sestamibi and other conventional radio-
pharmaceuticals in breast cancer diagnosis. Semin Nucl Med. 1999;
29(1):16-40.
15. Taillefer R. Clinical applications of 99mTc-sestamibi scintimammogra-
phy. Semin Nucl Med. 2005;35(2):100-15.
16. Gholamrezanezhad A, Mirpour S, Ardekani JM, Bagheri M,
Alimoghadam K, Yarmand S, et al. Cytotoxicity of 111In-oxine on
mesenchymal stem cells: a time-dependent adverse effect. Nucl Med
Commun. 2009;30(3):210-6, http://dx.doi.org/10.1097/MNM.0b013e328
318b328.
17. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging
modalities for the evaluation of breast cancer recurrence and metastases:
a meta-analysis. J Cancer Res Clin Oncol. 2010;136(7):1007-22, http://dx.
doi.org/10.1007/s00432-009-0746-6.
18. Ollivier L, Balu-Maestro C, Leclere J. Imaging in evaluation of response
to neoadjuvant breast cancer treatment. Cancer Imaging. 2005;5(1):27-31,
http://dx.doi.org/10.1102/1470-7330.2005.0009.
19. Gutfilen B, Fonseca LM. Comparison of Tc-99m THY and Tc-99m MIBI
scans for diagnosis of breast lesions. J Exp Clin Cancer Res.
2001;20(3):385-91.
20. Xu HB, Li L, Xu Q. Tc-99m sestamibi scintimammography for the
diagnosis of breast cancer: meta-analysis and meta-regression. Nucl Med
Commun. 2011;32(11):980-8, http://dx.doi.org/10.1097/MNM.0b013e
32834b43a9.
21. Planche K, Vinnicombe S. Breast imaging in the new era. Cancer
Imaging. 2004;4(2):39-50, http://dx.doi.org/10.1102/1470-7330.2003.
0033.
22. Gutfilen B, Rodrigues E, Soraggi R, Barbosa Da Fonseca LH. Preliminary
observation of 99mTc-thymine imaging in breast neoplasms. Nucl Med
Commun. 2001;22(10):1133-7, http://dx.doi.org/10.1097/00006231-200
110000-00013.
23. American_College_of_Radiology. Breast imaging report and data system
(BI-RADS). 4th ed. Reston, VA: American College of Radiology; 2003.
24. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2010;127(12):2893-917.
25. Green BB, Taplin SH. Breast cancer screening controversies. J Am Board
Fam Pract. 2003;16(3):233-41, http://dx.doi.org/10.3122/jabfm.16.3.233.
26. Scopinaro F, Schillaci O, Ussof W, Nordling K, Capoferro R, De Vincentis
G, et al. A three center study on the diagnostic accuracy of 99mTc-MIBI
scintimammography. Anticancer Res. 1997;17(3B):1631-4.
27. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobuty-
lisonitrile breast scintigraphy to evaluate palpable breast masses.
Eur J Nucl Med. 1994;21(5):432-6.
28. Khalkhali I, Villanueva-Meyer J, Edell SL, Connolly JL, Schnitt SJ, Baum
JK, et al. Diagnostic accuracy of 99mTc-sestamibi breast imaging:
multicenter trial results. J Nucl Med. 2000;41(12):1973-9.
29. Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, et al.
Scintimammography with technetium-99m methoxyisobutylisonitrile:
results of a prospective European multicentre trial. Eur J Nucl Med.
1998;25(4):375-85.
30. Liberman M, Sampalis F, Mulder DS, Sampalis JS. Breast cancer
diagnosis by scintimammography: a meta-analysis and review of the
literature. Breast Cancer Res Treat. 2003;80(1):115-26, http://dx.doi.org/
10.1023/A:1024417331304.
31. Tiling R, Stephan K, Sommer H, Shabani N, Linke R, Hahn K. Tissue-
specific effects on uptake of 99mTc-sestamibi by breast lesions: a targeted
analysis of false scintigraphic diagnoses. J Nucl Med. 2004;45(11):1822-8.
Figure 3 - A 58-year-old patient with a nodule (15 mm) in the
right breast and a mammographic BI-RADSH 4 (a nodule in the
right upper quadrant + microcalcifications). Breast scintigraphy
with 99mTc-thymine shows uptake in right breast. Histo-
pathological findings showed an infiltrating ductal carcinoma.
99mTc-thymine scan in breast cancer
Ribeiro MP et al.
CLINICS 2013;68(3):283-289
288
32. Khalkhali I, Itti E. Functional breast imaging using the single photon
technique. Nucl Med Commun. 2002;23(7):609-11, http://dx.doi.org/10.
1097/00006231-200207000-00003.
33. Sampalis FS, Denis R, Picard D, Fleiszer D, Martin G, Nassif E, et al.
International prospective evaluation of scintimammography with
(99m)technetium sestamibi. Am J Surg. 2003;185(6):544-9.
34. Mekhmandarov S, Sandbank J, Cohen M, Lelcuk S, Lubin E. Technetium-
99m-MIBI scintimammography in palpable and nonpalpable breast
lesions. J Nucl Med. 1998;39(1):86-91.
35. Tolmos J, Cutrone JA, Wang B, Vargas HI, Stuntz M, Mishkin FS, et al.
Scintimammographic analysis of nonpalpable breast lesions previously
identified by conventional mammography. J Natl Cancer Inst. 1998;90(11):846-9.
36. Fondrinier E, Muratet JP, Anglade E, Fauvet R, Berger V, Lorimier G,
et al. Clinical experience with 99mTc-MIBI scintimammography in
patients with breast microcalcifications. Breast. 2004;13(4):316-20, http://
dx.doi.org/10.1016/j.breast.2003.11.007.
37. Gommans GM, van der Zant FM, van Dongen A, Boer RO, Teule GJ, de
Waard JW. (99M)Technetium-sestamibi scintimammography in non-
palpable breast lesions found on screening X-ray mammography.
Eur J Surg Oncol. 2007;33(1):23-7.
38. Itti E, Ahdoot H, Khalkhali I. Scintimammography for the Diagnosis of
Breast Cancer. . Journal of Women’s Imaging. 2002;4(2):66-72, http://dx.
doi.org/10.1097/00130747-200205000-00005.
39. Prats E, Banzo J, Merono E, Herranz R, Carril JM. 99mTc-MIBI
scintimammography as a complement of the mammography in patients
with suspected breast cancer. A multicentre experience. Breast.
2001;10(2):109-16.
40. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins
JM, et al. Imaging DNA synthesis with [18F]FMAU and positron
emission tomography in patients with cancer. Eur J Nucl Med Mol
Imaging. 2005;32(1):15-22, http://dx.doi.org/10.1007/s00259-004-1713-
8.
CLINICS 2013;68(3):283-289 99mTc-thymine scan in breast cancer
Ribeiro MP et al.
289
